Hua Medicine (2552) H2 2019 earnings summary

Executive summary

• Dorzagliatin is positioned as a potential cornerstone therapy for type 2 diabetes, aiming to restore glucose homeostasis as monotherapy and in combination with existing drugs.

• Phase III monotherapy met its 24-week primary efficacy endpoint; reported HbA1c reduction was 1.07%, with hypoglycemia incidence below 1% and no severe cases.

• The 52-week monotherapy observation and 24-week metformin-combination study were completed; data review and quality checks remained before results.

Financial highlights

• FY19 cash outflow was CNY 337.7m; operating cash use was CNY 342m, including CNY 238m for R&D, and year-end cash was CNY 1.1bn.

• Accrued R&D expenses rose to CNY 321.9m from CNY 269m in 2018, primarily due to higher Phase III activity.

• Administrative expenses increased to CNY 146.6m from CNY 100m, reflecting team growth and commercial strategy consulting.

• Other income rose to CNY 29.6m; other gains fell to CNY 6.3m from CNY 63.8m as US dollar appreciation against the renminbi eased.

Outlook and guidance

• FY20 spending budget was CNY 700m; management cited year-end 2019 cash of CNY 1.1bn as a strong funding position.

• Top-line results from the completed Phase III studies were targeted for later in 2020, with COVID-19-related site access potentially delaying database lock and reporting.

• Market-entry preparation, payer adaptation and partner development were underway, with a planned China launch in 2021.

• Updates were planned for dorzagliatin combinations with DPP-4 and SGLT-2 inhibitors and for additional patient populations.